Archive
Proactive news round-up: ValiRx, ITM Power, Tharisa ...
A glance at some of the stories on the Proactive newswire today.
Company
LON:VAL
ValiRx is a drug development company, which focuses on the translation of scientific innovation into clinical candidates for cancer, related conditions and women’s health. The company's specialised business model connects science, finance and commerce to accelerate early-stage drug development. It identifies proprietary and novel drug candidates with the potential to improve patient lives, providing the expertise and investment required for optimised development and value creation.
309 stories · page 3 of 4
Archive
A glance at some of the stories on the Proactive newswire today.
Some of the main news-driven share price changes at 3.15pm
“[We are] entering a very exciting phase, which should result in the crystallisation of substantial value,” said chief executive, Dr Satu Vainikka.
FTSE 100 shares appear positively related to the Nasdaq as the London ticker again hits a fresh record high on Wednesday - its tenth successive
Archive
A glance at some of the stories on the Proactive newswire today
The notes were converted at 5.625p a share, versus a current share price of 5.15p..
Archive
A glance at today's headlines on the Proactive newswire ...
Archive
A glance at some of the main stories on the Proactive newswire today
Archive
A snapshot of the stories on the Proactive newswire today
The trial is a phase I/II dose escalation study to assess safety and tolerability
Also covered: Blur, Eckoh, Eurasia, FairFX, H&T, Rosslyn, KrisEnergy, Sierra Rutile, Tern, ValiRx, Xtract Resources
Members of the ValiSeek joint venture made a site visit to the clinic in Tbilisi, Georgia
Suddenly there’s cash swilling around the AIM natural resources sector, but the return of positive sentiment is too little too late for Xcite Energy.
The patents relate to the firm's compounds VAL201 and VAL401, which are currently in clinical trials
The company has two drugs in clinical trials, VAL 201 for prostate cancer, and VAL 401 for non-small cell lung cancer
The company has two drugs in clinical trials, VAL 201 for prostate cancer, and VAL 401 for non-small cell lung cancer
European Wealth Grouphas acquired CIMCO Partners Management Limited, ATTRAQT Group reports a boost to sales, and Westminster Group's ferry heads off on its maiden voyage.
“Studies continue to show preliminary indications of VAL201 positively effecting subjects' disease profile”
Paternoster Resources has taken a big stake in Polemos, which has done wonders for the latter's share price, but not Paternoster's
All approvals have now been granted for the trial, which will be carried out in Tbilisi, Georgia
Sareum Holdings plays down a recent report, Eurasia Mining agrees a refining contract and Minds + Machines is seeing exceptional growth.
ValiSeek Limited, the joint venture between ValiRx and Tangent Reprofiling Limited has received notification of a New Zealand patent grant allowance.
Carpet seller Victoria's results caught the eye, with revenue and adjusted EBITDA double what they were in the previous year
Having sold off its Finnish subsidiary earlier this month for €800,000 in cash, ValiRx has now terminated its convertible loan note facility with Bracknor.
The AIM-listed company, which is working with Tangent Reprofiling, said it had received a positive opinion recommending the trial protocol.
Leni Gas Cub shareholders unanimously approve reverse take-over bid, StratMin Global Resources enters into a conditional sale and purchase agreement with Bass Metals and progress at Rare EarthSonora lithium project in Mexico is going well.
The group will retain the licence to use TRAC technology (transcript analysis with the aid of affinity capture) in its development of therapeutic candidates.
Chilean copper miner did financing deals with two shareholders
FTSE AIM 100 was up 0.26% to 3,512, while the FTSE AIM All share gained 0.26% to stand at 745.290
ValiRx has also started preparatory work on a full efficacy study (phase III) of the drug in prostate cancer treatment.
Amur Minerals has pitched the potential of its Kun-Manie nickel project in Far East Russia to potential investors in Korea.
Pharma company shares rise as report urges action to develop super-bug treatments
A highlight of the year gone was Phase l/ll clinical trial of VAL201, which confirmed the compound was well tolerated and shown a high degree of safety.
Major share price risers and fallers in London at 3.30pm
People who measure such things say the chances of a rate hike in June have risen above 30%
The study will assess efficacy, safety and tolerability in people with the non-small cell variant of the disease where at least one form of chemotherapy has failed.
Life sciences firm ValiRx has been making progress on its lead drugs...
Fastjet agrees to early lease termination, ANGLE's cancer detection device takes off and Obtala agrees to full settlement.
Major share price risers and fallers in London at 4.00pm
The drug is targeting non-small-cell lung adenocarcinoma, the most common form of the disease.
Image Scan's losses slashed. Cloudbuy rises on contract win. Kolar Gold's new broker raises fears of impending share issue.
The American Association for Cancer Research Annual Conference will take place in New Orleans, starting April 16.
Petroleum plays Bankers Petroleum and Bahamas Petroleum were the highlights of the small-caps scene
Major share price risers and fallers in London at 4.15pm
The agreement will see Bracknor subscribe for the convertible loan notes in eight equal tranches of £0.5mln
Archive
Sirius Minerals' "world class" North Yorkshire project, update on Aureus and Allergy Therapeutics to lose finance director.
The Bank of England kept interest rates unchanged for the 84th month in a row.
Small cap shares were heading south in contrast to bigger brother FTSE100 but tech group Sopheon PLC was a notable riser.
Burns McClellan has already carried out an institutional investor introductory project for ValiRx.
ValiRx has one drug, VAL201, going through phase I/II trials
Below are the main news-driven share price changes at 1.00pm.
Archive
Specialist security group Westminster saw shares advance as cargo screening operations began at Freetown International Airport (FNA) in Sierra Leone, West Africa.
Those of you who dumped shares of cyber-security group Sophos ahead of today's trading update: good call!
VAL201 is currently going through a phase I/II trial for prostate cancer treatment.
Archive
Highlights of the news developments from the growth companies universe
Next steps will be a trial expansion phase, which will include centres in addition to UCH in London.
Archive
There were some fireworks at Proactive today... Alliance Pharma shares nudged higher on Thursday after it emerged it will receive £6.7mln in compensation.....
New office will also position it in close proximity to the biggest biotech market in the world.
Under the agreement, Pharmatest will design GeneICE constructs and test them in cancer model systems.
Investments and investor services
Shares in Atlantic Coal flew higher today but Ortac Resources took the top spot on the risers board.
ValiRx said the biomarkers separate types of B-cell lymphomas into different prognostic groups.
Its lead compound, VAL201, has passed safety controls and is showing early indications of efficacy even at low dosage.
The proceeds will help fund the drug developer’s therapeutic, biomarker and intellectual property developments.
Below are the main news-driven share price movements at 12.30pm.
Investments and investor services
Bank of England governor Mark Carney hopes the adoption of Three-In-One will oil the decision making process.
Professor Taylor has recently moved to the University of Leeds where helped develop VAL401, one of ValiRx's lead products.
Archive
Britain's top share index closed almost 20 points lower...
Archive
Pharma and biotech stocks were prominent and ValiRx shares were boosted....
Investments and investor services
blur Group attracted 30% more large business customers to its e-commerce platforms while Cable & Wireless reported flat first quarter mobile revenue.
"We are now nearing dose levels that we originally projected would be therapeutically significant.”
Archive
Shares in Jubilee Platinum soared today on disposal news....
The drug is being developed through a joint venture with Tangent Profiling.
Archive
Lekoil was boosted by the chief executive topping up his holding but there was some grim news elsewhere from the oil sector.